WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) will present new data from its Phase 2a trial of ATI-2138 in patients with moderate-to-severe atopic dermatitis at the 2026 American Academy of Dermatology Annual Meeting, the company announced.
The data will be shared in an electronic poster during the meeting in Denver and will include results not previously reported from the open-label study.
ATI-2138 is an investigational oral inhibitor targeting interleukin-2-inducible T cell kinase and Janus kinase 3, enzymes involved in immune system signaling.
The Phase 2a trial evaluated the therapy in patients with moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition.
The poster, titled “Results from an Open-Label Phase 2 Trial of ATI-2138…,” lists authors from Aclaris Therapeutics and the Icahn School of Medicine at Mount Sinai.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing treatments for immuno-inflammatory diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.